Media & Press Updates
What Happened in 2018
Evestra completes manufacturing facility
and re-elects board
January 25, 2018
European partner becomes equity shareholder as company celebrates 10 years
SCHERTZ, Texas – Evestra, Inc. this week celebrated the completion of its move to new headquarters and manufacturing facilities, the re-election of its board of directors, and the conversion of Gedeon Richter Plc.’s $5 million loan to an equity position in the company.
Evestra also marked the 10th anniversary of its incorporation as a spinoff from the Texas Biomedical Research Institute, based on that organization’s organic chemistry research over several decades.
“We’re excited about the future,” said Evestra President and CEO Ze’ev Shaked. “We have an innovative product pipeline based on two enabling platform technologies, a manufacturing operation in support of our products, excellent partners in Gedeon Richter and Glenmark Pharmaceuticals, 28 outstanding employees, and operations in three countries – the U.S., Germany, and Poland.”
Evestra shareholders re-elected all five of the company’s existing directors, including:
John Kerr, Chairman
Richard T. Schlosberg III
“It has been an honor to serve on this board with such an excellent team of people, who bring a vast depth and breadth of experience in pharmaceuticals, management, and leadership to Evestra,” Kerr said. “After 10 years of hard work, the 2008 vision has become a reality, and the company is well positioned for continued growth.”
Gedeon Richter signed three product-based collaboration agreements, including a 2014 agreement to extend to Evestra a $5-million convertible loan, which accelerated Evestra’s development of innovative women’s health products. Gedeon Richter, based in Budapest, Hungary, has opted to convert that loan into an equity stake.
Evestra’s new, 12,900-square-foot building in Schertz, just north of San Antonio, includes headquarters functions and a multi-product manufacturing facility that enables production of clinical and commercial products. This includes manufacturing of generic version of Merck & Co.’s NuvaRing® product – an etonogestrel/ethinyl estradiol vaginal ring – designed to allow women access to a more affordable birth control option.
With support from the City of Schertz, the manufacturing facility was designed and constructed by Angstrom Technology, a leader in cleanrooms manufacturing, while Brandt, a Texas-based company well known in construction of commercial facilities, provided mechanical and electrical engineering support.
Evestra is developing the product exclusively for Glenmark Pharmaceuticals for the U.S. market, with filing of an Abbreviated New Drug Application (ANDA) planned for the second half of 2018.
“We have developed innovative science, and production capabilities, for a range of women’s health products in areas such as hormone replacement, incontinence, birth control, endometriosis, and others,” said Klaus Nickisch, Evestra’s Chief Scientific Officer and Executive Vice President. “And now we have a truly world-class production facility to support development and commercialization of our women’s health product pipeline.”
Evestra, Inc. is a clinical-stage biopharmaceutical research and development company with a therapeutic focus in women’s healthcare. Evestra’s competitive advantage is based on its innovative product pipeline, strong intellectual property, strategic partnerships, prestigious grants, and its founders' experience and proven track record in drug development and commercializing women’s healthcare products.
EVESTRA AWARDED DEPARTMENT OF DEFENSE GRANT
February 26, 2018
The grant will support preclinical development of
first-in-class anticancer asset
SCHERTZ, Texas – Evestra, Inc. has received a grant from the Department of Defense (DoD) to develop a novel first-in-class LIF (Leukemia Inhibitory Factor) to treat triple negative breast cancer (TNBC).
The grant proposal, entitled “Targeted inhibition of Leukemia Inhibitory Factor (LIF/LIFR) Axis for the treatment of triple-negative breast cancer,” was submitted in collaboration with Dr. Ratna Vadlamudi from UT Health San Antonio, with Evestra Chief Scientific Officer Dr. Klaus Nickisch as principal investigator on behalf of Evestra. This is a three-year grant with Evestra receiving $960,000 while UT Health San Antonio will receive $761,298.
“This is an incredible achievement for Evestra for a number of reasons, said Dr. Ze’ev Shaked, President and CEO of Evestra “First, it is Evestra’s first home-grown drug discovery program in oncology to receive third-party validation. Second, it leverages Evestra’s medicinal chemistry know-how in the steroidal chemistry field into oncology, with all the ramifications that stem from it.”
“All the credit goes to Evestra’s drug discovery team that discovered that certain antiprogestin antagonists act as cytotoxic anti-tumor agents in the form of LIF inhibitors with applications in a wide-range of oncology indications,” Nickisch said.
Evestra has been collaborating with many prominent investigators and academic institutions in the US, and animal model studies were presented in oncology related meetings such as American Association for Cancer Research. As a result of the grant Evestra is pursuing preclinical development studies with the intend to file an IND.
Evestra, Inc. is a clinical-stage biopharmaceutical research and development company with a therapeutic focus in women’s healthcare. Evestra’s competitive advantage is based on its innovative product pipeline, strong intellectual property, strategic partnerships, prestigious grants, and its founders' experience and proven track record in drug development and commercializing women’s healthcare products. For more information about Evestra, visit www.Evestra.com.